Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine in Peripartum Cardiomyopathy
NCT02590601Phase 3Withdrawn
- Sponsor
- Montréal Heart Institute
- Start
- Jan 2017
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bromocriptine in Peripartum cardiomyopathy (PPCM), sponsored by Montréal Heart Institute. Planned start Jan 2017; status: withdrawn.
02
Drugs
bromocriptine
03
Conditions
Peripartum cardiomyopathy (PPCM)
Beyond the preview
Go deeper on NCT02590601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590601.